Reports Q3 revenue $1.52M, consensus $580,000. “During the third quarter, we were pleased to complete enrollment of our Phase 2 chronic spontaneous urticaria study well ahead of schedule. We look forward to presenting topline data from this study by end of year as we also plan for the potential advancement of barzolvolimab into registrational studies in 2024,” said Anthony Marucci, co-founder, president and CEO of Celldex Therapeutics. “Our Phase 1b study results in prurigo nodularis met our internal hurdle for advancement and we are actively planning for the initiation of a Phase 2 study early next year. We are excited to discuss these data next week in an oral presentation at the World Congress on itch and continue to deepen our leadership role in furthering the science of mast cell biology.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLDX:
- Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Celldex added to Q4 2023 Tactical Ideas List at Wells Fargo
- Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
- Celldex Therapeutics to Present at Cantor Global Healthcare Conference